Suprazygomatic Block in Cleft Palate Surgery in Children

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (53 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: paindosesundergoingcontrolleduse of
  Phrases that lowered it: nervoussmallused ingrouppatients
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 307 (raises risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Minimum age: 1 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 13.3% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 70.4% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 48865 (raises risk) · Drug's FDA history
• Sponsor's past trials: 162 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports before start: 266496 (lowers risk) · Drug's FDA history
• Maximum age: 5 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery NCT02923869 · started 2016 · scored riskier than 23% of active trials completed
• Nalbuphine as Adjuvant During Bilateral Suprazygomatic Maxillary Nerve Block for Pediatric Cleft Palate Repair NCT06100315 · started 2023 · scored riskier than 4% of active trials completed
• Dexmedetomidine Versus Magnesium Sulphate Added to Bupivacaine in Infraorbital Nerve Block for Perioperative Analgesia in Paediatric Patients for Cleft Lip Surgery NCT05624151 · started 2022 · scored riskier than 11% of active trials completed
• Infra-orbital Nerve Block for Post Operative Analgesia in Children Undergoing Cleft Lip Surgery. NCT02514980 · started 2015 · scored riskier than 11% of active trials completed
• A Single Bolus of Dexmedetomidine Versus Normal Saline in Postoperative Agitation NCT04928391 · started 2021 · scored riskier than 10% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.